Midatech Pharma PlcのBeta
Midatech Pharma PlcのBetaは何ですか。
Midatech Pharma PlcのBetaは1.60です。
Betaの定義は何ですか。
BETAは、株式が市場全体よりも多かれ少なかれ揮発性であるかどうかを示します。 1未満のベータは株式が市場よりも揮発性が低いことを示し、1より大きいベータは株式がより揮発性であることを示します。ボラティリティは、平均値周辺の価格の変動として測定されます。
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
LSEのセクタHealth CareにおけるBetaの企業と比べるMidatech Pharma Plc
Midatech Pharma Plcは何をしますか。
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Midatech Pharma Plcと類似のbeta
- European MetalsのBetaは1.60です。
- European MetalsのBetaは1.60です。
- Entercom Communications CorpのBetaは1.60です。
- Castile ResourcesのBetaは1.60です。
- Castile ResourcesのBetaは1.60です。
- Aberdeen InternationalのBetaは1.60です。
- Midatech Pharma PlcのBetaは1.60です。
- Shivalik RasayanのBetaは1.60です。
- Designer Brands IncのBetaは1.60です。
- Amarc ResourcesのBetaは1.60です。
- Avante LogixxのBetaは1.60です。
- EchoStar CorpのBetaは1.60です。
- Marathon PetroleumのBetaは1.60です。